Systemic therapy of metastatic bladder cancer in the molecular era: current status and future promise

Bibliography

• Jemal A, Siegel R, Ward E, Cancer statistics, 2009. CA Cancer J Clin 2009;19(4):225-49
   Google Scholar
• Dinney CP. Therapy of invasive bladder cancer. Urology 2006;67(3 Suppl 1):56-9; discussion 60-1
   PubMedGoogle Scholar
• Stein JP, Lieskovsky G, Cote R, Radical cystectomy in the treatment of invasive bladder cancer: long-term results in 1,054 patients. J Clin Oncol 2001;19(3):666-75
   PubMed Web of Science ®Google Scholar
• Bajorin DF, Dodd PM, Mazumdar M, Long-term survival in metastatic transitional-cell carcinoma and prognostic factors predicting outcome of therapy. J Clin Oncol 1999;17(10):3173-81
   PubMed Web of Science ®Google Scholar
• Von der Maase H, Hansen SW, Roberts JT, Gemcitabine and cisplatin versus methotrexate, vinblastine, doxorubicin, and cisplatin in advanced or metastatic bladder cancer: results of a large, randomized, multinational, multicenter, phase III study. J Clin Oncol 2000;18(17):3068-77
   PubMed Web of Science ®Google Scholar
• Culine S, Theodore C, De Santis M, A phase II study of vinflunine in bladder cancer patients progressing after first-line platinum-containing regimen. Br J Cancer 2006;94(10):1395-401
   PubMed Web of Science ®Google Scholar
• Logothetis CJ, Dexeus FH, Finn L, A prospective randomized trial comparing MVAC and CISCA chemotherapy for patients with metastatic urothelial tumors. J Clin Oncol 1990;8(6):1050-5
   PubMed Web of Science ®Google Scholar
• Loehrer PJ Sr, Einhorn LH, Elson PJ, A randomized comparison of cisplatin alone or in combination with methotrexate, vinblastine, and doxorubicin in patients with metastatic urothelial carcinoma: a cooperative group study. J Clin Oncol 1992;10(7):1066-73
   PubMed Web of Science ®Google Scholar
• Sternberg CN, Calabro F, Pizzocaro G, Chemotherapy with an every-2-week regimen of gemcitabine and paclitaxel in patients with transitional cell carcinoma who have received prior cisplatin-based therapy. Cancer 2001;92(12):2993-8
   PubMed Web of Science ®Google Scholar
• Siefker-Radtke AO, Millikan RE, Tu SM, Phase III trial of fluorouracil, interferon alpha-2b, and cisplatin versus methotrexate, vinblastine, doxorubicin, and cisplatin in metastatic or unresectable urothelial cancer. J Clin Oncol 2002;20(5):1361-7
   PubMed Web of Science ®Google Scholar
• Bamias A, Aravantinos G, Deliveliotis C, Docetaxel and cisplatin with granulocyte colony-stimulating factor (G-CSF) versus MVAC with G-CSF in advanced urothelial carcinoma: a multicenter, randomized, phase III study from the Hellenic Cooperative Oncology Group. J Clin Oncol 2004;22(2):220-8
   PubMed Web of Science ®Google Scholar
• Dreicer R, Manola J, Roth BJ, Phase III trial of methotrexate, vinblastine, doxorubicin, and cisplatin versus carboplatin and paclitaxel in patients with advanced carcinoma of the urothelium. Cancer 2004;100(8):1639-45
   PubMed Web of Science ®Google Scholar
• Von der Maase H, Sengelov L, Roberts JT, Long-term survival results of a randomized trial comparing gemcitabine plus cisplatin, with methotrexate, vinblastine, doxorubicin, plus cisplatin in patients with bladder cancer. J Clin Oncol 2005;23(21):4602-8
   PubMed Web of Science ®Google Scholar
• National Comprehensive Cancer Network (NCCN) website. Available at www.nccn.org
   Google Scholar
• Bellmunt J, Albiol S, Kataja V. Invasive bladder cancer: ESMO clinical recommendations for diagnosis, treatment and follow-up. Ann Oncol 2008;19(Suppl 2):ii47-8
   PubMedGoogle Scholar
• Bellmunt J, von der Maase H, Mead GM, Randomized phaseIII study comparing paclitaxel/cisplatin/gemcitabine and gemcitabine/cisplatin in patients with locally advanced or metastatic urothelial cancer without prior systemic therapy. EORTC30987/Intergroup Study [abstract LBA5030]. 2007 Asco Annual Meeting Proceedings; 1 – 5 June; Chicago, IL, USA; J Clin Oncol 2007
   Google Scholar
• Saxman SB, Propert KJ, Einhorn LH, Long-term follow-up of a phase III intergroup study of cisplatin alone or in combination with methotrexate, vinblastine, and doxorubicin in patients with metastatic urothelial carcinoma: a cooperative group study. J Clin Oncol 1997;15(7):2564-9
   PubMed Web of Science ®Google Scholar
• Bachner M, De Santis M. Second-line therapy in bladder cancer. Curr Opin Urol 2009;19(5):533-9
   PubMed Web of Science ®Google Scholar
• Gallagher DJ, Milowsky MI, Bajorin DF. Advanced bladder cancer: status of first-line chemotherapy and the search for active agents in the second-line setting. Cancer 2008;113(6):1284-93
   PubMed Web of Science ®Google Scholar
• Dreicer R, Li S, Manola J, Phase 2 trial of epothilone B analog BMS-247550 (ixabepilone) in advanced carcinoma of the urothelium (E3800): a trial of the Eastern Cooperative Oncology Group. Cancer 2007;110(4):759-63
   PubMed Web of Science ®Google Scholar
• Sweeney CJ, Roth BJ, Kabbinavar FF, Phase II study of pemetrexed for second-line treatment of transitional cell cancer of the urothelium. J Clin Oncol 2006;24(21):3451-7
   PubMed Web of Science ®Google Scholar
• Bellmunt J, Theodore C, Demkov T, Phase III trial of vinflunine plus best supportive care compared with best supportive care alone after a platinum-containing regimen in patients with advanced transitional cell carcinoma of the urothelial tract. J Clin Oncol 2009;27(27):4454-61
   PubMed Web of Science ®Google Scholar
• Garcia JA, Dreicer R. Systemic chemotherapy for advanced bladder cancer: update and controversies. J Clin Oncol 2006;24(35):5545-51
   PubMed Web of Science ®Google Scholar
• Rajkumar T, Stamp GW, Pandha HS, Expression of the type 1 tyrosine kinase growth factor receptors EGF receptor, c-erbB2 and c-erbB3 in bladder cancer. J Pathol 1996;179(4):381-5
   PubMed Web of Science ®Google Scholar
• Philips GK, Halabi S, Sanford BL, A phase II trial of cisplatin (C), gemcitabine (G) and gefitinib for advanced urothelial tract carcinoma: results of Cancer and Leukemia Group B (CALGB) 90102. Ann Oncol 2009;20(6):1074-9
   PubMed Web of Science ®Google Scholar
• Sriplakich S, Jahnson S, Karlsson MG. Epidermal growth factor receptor expression: predictive value for the outcome after cystectomy for bladder cancer? BJU Int 1999;83(4):498-503
   PubMed Web of Science ®Google Scholar
• Dominguez-Escrig JL, Kelly JD, Neal DE, Evaluation of the therapeutic potential of the epidermal growth factor receptor tyrosine kinase inhibitor gefitinib in preclinical models of bladder cancer. Clin Cancer Res 2004;10(14):4874-84
   PubMed Web of Science ®Google Scholar
• Neal DE, Sharples L, Smith K, The epidermal growth factor receptor and the prognosis of bladder cancer. Cancer 1990;65(7):1619-25
   PubMed Web of Science ®Google Scholar
• Petrylak D, Faulkner JR, Van Veldhuizen PJ, New York Presbyterian Hospital, New York, NY; Southwest Oncology Group Statistical Center, Seattle, WA; Veterans Affairs Medical Center, Kansas City, MO; University of Colorado, Denver, CO. Evaluation of ZD1839 for advanced transitional cell carcinoma (TCC) of the urothelium: A Southwest Oncology Group Trial. Proc Am Soc Clin Oncol: 2003;22: abstract 1619
   PubMedGoogle Scholar
• MDAC: M D. Anderson Cancer Center: Iressa and Taxotere Study in patients with metastatic urothelial cancer. ClinicalTrialsgov Identifier: NCT00479089
   Google Scholar
• Jin Y, Iwata KK, Belldegrun A, Effect of an epidermal growth factor receptor tyrosine kinase inhibitor on actin remodeling in an in vitro bladder cancer carcinogenesis model. Mol Cancer Ther 2006;5(7):1754-63
   PubMed Web of Science ®Google Scholar
• Pruthi RS, Nielsen M, Heathcote S, A phase II trial of neoadjuvant erlotinib in patients with muscle-invasive bladder cancer undergoing radical cystectomy: clinical and pathological results. BJU Int 2010. [Epub ahead of print]
   Google Scholar
• Perrotte P, Matsumoto T, Inoue K, Anti-epidermal growth factor receptor antibody C225 inhibits angiogenesis in human transitional cell carcinoma growing orthotopically in nude mice. Clin Cancer Res 1999;5(2):257-65
   PubMed Web of Science ®Google Scholar
• Inoue K, Slaton JW, Perrotte P, Paclitaxel enhances the effects of the anti-epidermal growth factor receptor monoclonal antibody ImClone C225 in mice with metastatic human bladder transitional cell carcinoma. Clin Cancer Res 2000;6(12):4874-84
   PubMed Web of Science ®Google Scholar
• Michigan University: Study of gemcitabine and cisplatin with or without cetuximab in urothelial cancer. Clinical-Trials.gov identifier NCT00645593. US National Institutes of Health
   Google Scholar
• Jimenez RE, Hussain M, Bianco FJ Jr, Her-2/neu overexpression in muscle-invasive urothelial carcinoma of the bladder: prognostic significance and comparative analysis in primary and metastatic tumors. Clin Cancer Res 2001;7(8):2440-7
   PubMed Web of Science ®Google Scholar
• Hussain MH, MacVicar GR, Petrylak DP, Trastuzumab, paclitaxel, carboplatin, and gemcitabine in advanced human epidermal growth factor receptor-2/neu-positive urothelial carcinoma: results of a multicenter phase II National Cancer Institute trial. J Clin Oncol 2007;25(16):2218-24
   PubMed Web of Science ®Google Scholar
• RTOG: Radiation Therapy Oncology Group. Paclitaxel and radiation therapy with or without trastuzumab in treating patients who have undergone surgery for bladder cancer. ClinicalTrialsgov Identifier: NCT00238420
   Google Scholar
• Clark TW, Cohen RA, Kwak A, Salvage of nonmaturing native fistulas by using angioplasty. Radiology 2007;242(1):286-92
   PubMed Web of Science ®Google Scholar
• Beuzeboc P, Banu E, Voog E, Trastuzumab (T) combined with standard chemotherapy in HER+ metastatic bladder cancer (BC) patients: Interim safety results of a prospective randomized phase II study. 2007 ASCO Annual Meeting Proceedings Part I. J Clin Oncol 2007;25(18S):15565
   Google Scholar
• Medina PJ, Goodin S. Lapatinib: a dual inhibitor of human epidermal growth factor receptor tyrosine kinases. Clin Ther 2008;30(8):1426-47
   PubMed Web of Science ®Google Scholar
• McHugh LA, Sayan AE, Mejlvang J, Lapatinib, a dual inhibitor of ErbB-1/-2 receptors, enhances effects of combination chemotherapy in bladder cancer cells. Int J Oncol 2009;34(4):1155-63
   PubMed Web of Science ®Google Scholar
• Wulfing C, Machiels JP, Richel DJ, A single-arm, multicenter, open-label phase 2 study of lapatinib as the second-line treatment of patients with locally advanced or metastatic transitional cell carcinoma. Cancer 2009;115(13):2881-90
   PubMed Web of Science ®Google Scholar
• Orchid Clinical Trials Group at Barts and the London School of Medicine and Dentistry. Lapatinib ditosylate in treating patients with stage IV bladder cancer. ClinicalTrialsgov Identifier: NCT00949455
   Google Scholar
• Galsky MD, Von Hoff DD, Neubauer M, Target-specific, histology-independent, randomized discontinuation study of lapatinib in patients with HER2-amplified solid tumors. 2009 ASCO Annual meeting. J Clin Oncol 2009;27(15s): abstract 3541
   Google Scholar
• Korkolopoulou P KA, Kavantzas N, Patsouris E, Morphometric microvascular characteristics predict prognosis in superficial and invasive bladder cancer. Virchows Arch 2001;438:603-11
   PubMed Web of Science ®Google Scholar
• Stein JP, Grossfeld GD, Ginsberg DA, Prognostic markers in bladder cancer: a contemporary review of the literature. J Urol 1998;160(3 Pt 1):645-59
   PubMed Web of Science ®Google Scholar
• Shao ZM, Nguyen M. Angiogenic factors and bladder cancer. Front Biosci 2002;7:e33-5
   PubMed Web of Science ®Google Scholar
• Bernardini S, Fauconnet S, Chabannes E, Serum levels of vascular endothelial growth factor as a prognostic factor in bladder cancer. J Urol 2001;166(4):1275-9
   PubMed Web of Science ®Google Scholar
• Jones A, Crew J. Vascular endothelial growth factor and its correlation with superficial bladder cancer recurrence rates and stage progression. Urol Clin North Am 2000;27(1):191-7
   PubMed Web of Science ®Google Scholar
• Chopin DK, Caruelle JP, Colombel M, Increased immunodetection of acidic fibroblast growth factor in bladder cancer, detectable in urine. J Urol 1993;150(4):1126-30
   PubMed Web of Science ®Google Scholar
• O'Brien TS, Smith K, Cranston D, Urinary basic fibroblast growth factor in patients with bladder cancer and benign prostatic hypertrophy. Br J Urol 1995;76(3):311-4
   PubMedGoogle Scholar
• Gravas S, Bosinakou I, Kehayas P, Giannopoulos A. Urinary basic fibroblast growth factor in bladder cancer patients. Histopathological correlation and clinical potential. Urol Int 2004;73(2):173-7
   PubMed Web of Science ®Google Scholar
• Folkman J. Seminars in medicine of the Beth Israel Hospital, Boston. Clinical applications of research on angiogenesis. N Engl J Med 1995;333(26):1757-63
   PubMed Web of Science ®Google Scholar
• Mitra AP, Lin H, Datar RH, Cote RJ. Molecular biology of bladder cancer: prognostic and clinical implications. Clin Genitourin Cancer 2006;5(1):67-77
   PubMed Web of Science ®Google Scholar
• Inoue K, Slaton JW, Karashima T, The prognostic value of angiogenesis factor expression for predicting recurrence and metastasis of bladder cancer after neoadjuvant chemotherapy and radical cystectomy. Clin Cancer Res 2000;6(12):4866-73
   PubMed Web of Science ®Google Scholar
• Yang CC, Chu KC, Yeh WM. The expression of vascular endothelial growth factor in transitional cell carcinoma of urinary bladder is correlated with cancer progression. Urol Oncol 2004;22(1):1-6
   PubMed Web of Science ®Google Scholar
• Medical University of South Carolina: Cisplatin, Bevacizumab, and Gemcitabine Followed by Surgery, Bevacizumab, and Paclitaxel in treating patients with locally advanced nonmetastatic bladder cancer that can be removed by surgery. June 2009. ClinicalTrials.gov Identifier: NCT00268450
   Google Scholar
• Hahn NM, Stadler WM, Zon RT, Waterhouse DM. A multicenter phase II study of cisplatin (C), gemcitabine (G), and bevacizumab (B) as first-line chemotherapy for metastatic urothelial carcinoma (UC): Hoosier Oncology Group GU-0475. 2009 ASCO Annual Meeting J Clin Oncol 2009;27(15s): abstract 5018
   Google Scholar
• CALG: Cancer Leucemia Group B Gemcitabine Hydrochloride and Cisplatin with or without bevacizumab in treating patients with advanced urinary tract cancer. ClinicalTrialsgov Identifier: NCT00942331
   Google Scholar
• Chu QS. Aflibercept (AVE0005): an alternative strategy for inhibiting tumour angiogenesis by vascular endothelial growth factors. Expert Opin Biol Ther 2009;9(2):263-71
   PubMed Web of Science ®Google Scholar
• Twardowski P, StadlerW M, Frankel P, Phase II study of aflibercept (VEGF-Trap) in patients (pts) with recurrent or metastatic transitional cell carcinoma (TCC) of the urothelium. A California Cancer Consortium trial. J Clin Oncol 2009;27: abstract e16030
   PubMed Web of Science ®Google Scholar
• Sonpavde G, Jian W, Liu H, Sunitinib malate is active against human urothelial carcinoma and enhances the activity of cisplatin in a preclinical model. Urol Oncol 2009;27(4):391-9
   PubMed Web of Science ®Google Scholar
• Gallagher DJ, Milowsky MI, Gerst SR, Phase II study of sunitinib in patients with metastatic urothelial cancer. J Clin Oncol 2010;28(8):1373-9
   Google Scholar
• Gallagher DJ, MIlowsky MI, GerstS RS, A phase II study of sunitinib on a continuous dosing schedule in patients (pts) with relapsed or refractory urothelial carcinoma (UC). 2009 ASCO Annual Meeting. J Clin Oncol 2009;27(15s): abstract 5072
   Google Scholar
• Bellmunt J MP, Mellado B, Carles J, Phase II study of sunitinib as first line treatment in aptients with advanced urothelial cancer ineligible for cisplatin-based chemotherapy. Genitourin Cancer Symp 2008: abstract 291
   Google Scholar
• Bradley D, Daignault S, Smith DC, 2009 ASCO Annual Meeting. J Clin Oncol 2009;27(15s): abstract 5073
   PubMedGoogle Scholar
• Mackenzie MJ, Winquist E, Rodrigues G. Open clinical uro-oncology trials in Canada. Can J Urol 2010;17(1):5050-6
   PubMedGoogle Scholar
• Available from: http://clinicaltrials.gov/ct2/show/NCT00859339, Hoosier Oncology Group HOG. Neoadjuvant cisplatin, gemcitabine, sunitinib malate + radical cystectomy for transitional cell carcinoma (TCC) of the bladder
   Google Scholar
• MS-KC: Memorial Sloan-Kettering Cancer Center: gemcitabine, cisplatin, and sunitinib (GC-S) as neoadjuvant chemotherapy in patients with muscle-invasive bladder cancer. ClinicalTrialsgov Identifier: NCT00847015
   Google Scholar
• Dreicer R, Li H, Stein M, Phase 2 trial of sorafenib in patients with advanced urothelial cancer: a trial of the Eastern Cooperative Oncology Group. Cancer 2009;115(18):4090-5
   PubMed Web of Science ®Google Scholar
• Sridhar SS, Winquist E, Eisen A, A phase II study of first-line sorafenib (Bay 43-9006) in advanced or metastatic urothelial cancer. A trial of the PMH Phase II Consortium [abstract]. 2008 Genitourin Cancer Symp
   Google Scholar
• Sonpavde G, Sternberg CN. Treatment of metastatic urothelial cancer: opportunities for drug discovery and development. BJU Int 2008;102(9 Pt B):1354-60
   PubMed Web of Science ®Google Scholar
• Hurwitz HI, Dowlati A, Saini S, Phase I trial of pazopanib in patients with advanced cancer. Clin Cancer Res 2009;15(12):4220-7
   PubMed Web of Science ®Google Scholar
• Mayo Clinic: pazopanib in treating patients with metastatic urothelial cancer. ClinicalTrials.gov Identifier: NCT00471536
   Google Scholar
• Holden SN, Eckhardt SG, Basser R, Clinical evaluation of ZD6474, an orally active inhibitor of VEGF and EGF receptor signaling, in patients with solid, malignant tumors. Ann Oncol 2005;16(8):1391-7
   PubMed Web of Science ®Google Scholar
• Flaig TW, Su LJ, McCoach C, Dual epidermal growth factor receptor and vascular endothelial growth factor receptor inhibition with vandetanib sensitizes bladder cancer cells to cisplatin in a dose- and sequence-dependent manner. BJU Int 2009;103(12):1729-37
   PubMed Web of Science ®Google Scholar
• Dana-Farber Cancer Institute: docetaxel with or without vandetanib in treating patients with previously treated stage IV transitional cell cancer. ClinicalTrials.gov Identifier: NCT00378794
   Google Scholar
• Gromet MA, Epstein WL, Blois MS. The regressing thin malignant melanoma: a distinctive lesion with metastatic potential. Cancer 1978;42(5):2282-92
   PubMed Web of Science ®Google Scholar
• Knuth A, Wolfel T, Klehmann E, Cytolytic T-cell clones against an autologous human melanoma: specificity study and definition of three antigens by immunoselection. Proc Natl Acad Sci USA 1989;86(8):2804-8
   PubMed Web of Science ®Google Scholar
• Wolfel T, Klehmann E, Muller C, Lysis of human melanoma cells by autologous cytolytic T cell clones. Identification of human histocompatibility leukocyte antigen A2 as a restriction element for three different antigens. J Exp Med 1989;170(3):797-810
   PubMed Web of Science ®Google Scholar
• Blansfield JA, Beck KE, Tran K, Cytotoxic T-lymphocyte-associated antigen-4 blockage can induce autoimmune hypophysitis in patients with metastatic melanoma and renal cancer. J Immunother 2005;28(6):593-8
   PubMed Web of Science ®Google Scholar
• Korman A, Yellin M, Keler T. Tumor immunotherapy: preclinical and clinical activity of anti-CTLA4 antibodies. Curr Opin Investig Drugs 2005;6(6):582-91
   PubMedGoogle Scholar
• Peggs KS, Quezada SA, Allison JP. Cell intrinsic mechanisms of T-cell inhibition and application to cancer therapy. Immunol Rev 2008;224:141-65
   PubMed Web of Science ®Google Scholar
• Sun J, Schiffman J, Raghunath A, Concurrent decrease in IL-10 with development of immune-related adverse events in a patient treated with anti-CTLA-4 therapy. Cancer Immun 2008;8:9
   PubMedGoogle Scholar
• Zhou H, Kuang J, Zhong L, Tumour amplified kinase STK15/BTAK induces centrosome amplification, aneuploidy and transformation. Nat Genet 1998;20(2):189-93
   PubMed Web of Science ®Google Scholar
• Bischoff JR, Anderson L, Zhu Y, A homologue of Drosophila aurora kinase is oncogenic and amplified in human colorectal cancers. Embo J 1998;17(11):3052-65
   PubMed Web of Science ®Google Scholar
• Pugacheva EN, Golemis EA. The focal adhesion scaffolding protein HEF1 regulates activation of the Aurora-A and Nek2 kinases at the centrosome. Nat Cell Biol 2005;7(10):937-46
   PubMed Web of Science ®Google Scholar
• Park HS, Park WS, Bondaruk J, Quantitation of Aurora kinase A gene copy number in urine sediments and bladder cancer detection. J Natl Cancer Inst 2008;100(19):1401-11
   PubMed Web of Science ®Google Scholar
• Faivre S, Djelloul S, Raymond E. New paradigms in anticancer therapy: targeting multiple signaling pathways with kinase inhibitors. Semin Oncol 2006;33(4):407-20
   PubMed Web of Science ®Google Scholar
• Dalbagni G, Presti J, Reuter V, Genetic alterations in bladder cancer. Lancet 1993;342(8869):469-71
   PubMed Web of Science ®Google Scholar
• Konstantinopoulos PA, Karamouzis MV, Papavassiliou AG. Post-translational modifications and regulation of the RAS superfamily of GTPases as anticancer targets. Nat Rev Drug Discov 2007;6(7):541-55
   PubMedGoogle Scholar
• Winquist E, Moore MJ, Chi KN, A multinomial Phase II study of lonafarnib (SCH 66336) in patients with refractory urothelial cancer. Urol Oncol 2005;23(3):143-9
   PubMed Web of Science ®Google Scholar
• Theodore C, Geoffrois L, Vermorken JB, Multicentre EORTC study 16997: feasibility and phase II trial of farnesyl transferase inhibitor & gemcitabine combination in salvage treatment of advanced urothelial tract cancers. Eur J Cancer 2005;41(8):1150-7
   PubMed Web of Science ®Google Scholar
• Konstantinopoulos PA, Papavassiliou AG. 17-AAG: mechanisms of antitumour activity. Expert Opin Investig Drugs 2005;14(12):1471-4
   PubMed Web of Science ®Google Scholar
• Wang JY, Wilcoxen KM, Nomoto K, Wu S. Recent advances of MEK inhibitors and their clinical progress. Curr Top Med Chem 2007;7(14):1364-78
   PubMed Web of Science ®Google Scholar
• Li N, Batt D, Warmuth M. B-Raf kinase inhibitors for cancer treatment. Curr Opin Investig Drugs 2007;8(6):452-6
   PubMed Web of Science ®Google Scholar
• Nelson J, Bagnato A, Battistini B, Nisen P. The endothelin axis: emerging role in cancer. Nat Rev Cancer 2003;3(2):110-6
   PubMed Web of Science ®Google Scholar
• Wulfing C, Eltze E, Piechota H, Expression of endothelin-1 and endothelin-A and -B receptors in invasive bladder cancer. Oncol Rep 2005;13(2):223-8
   PubMed Web of Science ®Google Scholar
• Wulfing C, Eltze E, Yamini J, Expression of the endothelin axis in bladder cancer: relationship to clinicopathologic parameters and long-term survival. Eur Urol 2005;47(5):593-600
   PubMed Web of Science ®Google Scholar
• Herrmann E, Bogemann M, Bierer S, The role of the endothelin axis and microvessel density in bladder cancer – correlation with tumor angiogenesis and clinical prognosis. Oncol Rep 2007;18(1):133-8
   PubMed Web of Science ®Google Scholar
• Carmeliet P, Jain RK. Angiogenesis in cancer and other diseases. Nature 2000;407(6801):249-57
   PubMed Web of Science ®Google Scholar
• Mita AC, Wang D, Takimoto CH, Amg 386, a selective angiopoietin 1/2-neutralizing peptibody, in combination with chemotherapy in adult patients with advanced solid tumors. Meeting abstracts. J Clin Oncol 2007;25:14033
   Google Scholar
• Cappellen D, De Oliveira C, Ricol D, Frequent activating mutations of FGFR3 in human bladder and cervix carcinomas. Nat Genet 1999;23(1):18-20
   PubMed Web of Science ®Google Scholar
• Novartis Pharmaceuticals. Phase II Study of TKI258 in Advanced Urothelial Carcinoma. ClinicalTrialsgov Identifier: NCT00790426
   Google Scholar
• Sridhar SS, Canil CM, Mukherjee SD, Princess Margaret Hospital, Toronto, ON, Canada; Ottawa Regional Cancer Center, Ottawa, ON, Canada; Juravinski Cancer Centre, Hamilton, ON, Canada; London Regional Cancer Centre, London, ON, Canada; Sunnybrook Odette Cancer Centre, Toronto, ON, Canada A phase II study of single-agent nab-paclitaxel as second-line therapy in patients with metastatic urothelial carcinoma. ASCO Annual Meeting 2010
   Google Scholar
• Takai N, Hamanaka R, Yoshimatsu J, Miyakawa I. Polo-like kinases (Plks) and cancer. Oncogene 2005;24(2):287-91
   PubMed Web of Science ®Google Scholar
• Boehringer Ingelheim Pharmaceuticals. Intravenous BI 6727 in 2nd Line Treatment of Urothelial Cancer. ClinicalTrialsgov Identifier: NCT01023958
   Google Scholar
• Brunton VG, Frame MC. Src and focal adhesion kinase as therapeutic targets in cancer. Curr Opin Pharmacol 2008;8(4):427-32
   PubMed Web of Science ®Google Scholar
• Johnson FM, Saigal B, Talpaz M, Donato NJ. Dasatinib (BMS-354825) tyrosine kinase inhibitor suppresses invasion and induces cell cycle arrest and apoptosis of head and neck squamous cell carcinoma and non-small cell lung cancer cells. Clin Cancer Res 2005;11(19 Pt 1):6924-32
   PubMed Web of Science ®Google Scholar
• Nam S, Kim D, Cheng JQ, Action of the Src family kinase inhibitor, dasatinib (BMS-354825), on human prostate cancer cells. Cancer Res 2005;65(20):9185-9
   PubMed Web of Science ®Google Scholar
• Levitt JM, Yamashita H, Jian W, Dasatinib is preclinically active against Src-overexpressing human transitional cell carcinoma of the urothelium with activated Src signaling. Mol Cancer Ther 2010;9(5):1128-35
   PubMed Web of Science ®Google Scholar